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Abstract
Visceral leishmaniasis in South Asia is a serious disease affecting children and adults. Acute visceral leishmaniasis develops in only a fraction
of those infected individuals, the majority being asymptomatic with the potential to transmit infection and develop disease. We followed 56
individuals characterized as being asymptomatic by seropositivity with rk39 rapid diagnostic test in a hyperendemic district of Bangladesh to
deﬁne the utility of Leishmania-speciﬁc antibodies and DNA in identifying infection. At baseline, 54 of the individuals were seropositive with
one or more quantitative antibody assays and antibody levels persisted at follow up. Most seropositive individuals (47/54) tested positive by
quantitative PCR at baseline, but only 16 tested positive at follow up. The discrepancies among the different tests may shed light on the
dynamics of asymptomatic infections of Leishmania donovani, as well as underscore the need for standard diagnostic tools for active
surveillance as well as assessing the effectiveness of prophylactic and therapeutic interventions.
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Introduction
One of the characteristics of neglected diseases is the lack of
tools for successful disease management or prevention. As an
example, it has only been recently that tools to detect infected
individuals have begun to be applied in regions where
Leishmania donovani is endemic. Leishmania are vector-borne
protozoan parasites spread by the bite of the infected
phlebotomine sand-ﬂy [1,2]. Two Leishmania spp. cause
visceral leishmaniasis (VL; also known as kala-azar), which is
the most severe form, often fatal if not treated [3]. Half a
million new VL cases are diagnosed every year and, with a
mortality rate of 10%, VL is second only to malaria in terms of
fatality [4].
In the Indian subcontinent VL is caused by L. donovani. An
estimated100 000VL cases are reported annually in the endemic
foci of northeastern India, Nepal and Bangladesh, costing
400 000 disability-adjusted life-years and putting 150 million
people at risk for infection[5] The situation in this region, where
humans are the only reservoir of the parasite, makes elimination
feasible [3]. In 2005 these three countries committed to a
kala-azar elimination programme, with the intent of decreasing
incidence to 1 in 10 000 per year by 2015 [6]. Goals of the
programme include early diagnosis and treatment, coordinated
vector control and effective disease surveillance through passive
and active case detection [7]. A pressing concern that could
interfere with this goal is the presence of large populations who
harbour infection with no overt signs of disease but who can
potentially develop VL and probably spread infection [8,9].
Considerably more asymptomatic individuals than those with VL
disease are identiﬁed in areas of endemicity [10,11].
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Traditionally, both direct (detection of parasites) and
indirect (detection of antibodies) tests have been used in the
diagnosis of VL. The standard diagnostic method for VL has
been microscopic visualization of amastigotes in splenic, lymph
node or bone marrow aspirates, ethically and technically
unsuitable for asymptomatic individuals [12]. The kala-azar
elimination programme does not evaluate asymptomatic
individuals because deﬁned parameters to identify low levels
of infection are lacking. A limited number of antibody
detection tests, including the direct agglutination test (DAT),
ELISA and immunochromatography-based rapid tests, have
been standardized [12]. Given the endemic nature of L. dono-
vani infection, serological tests lack the ability to discern
between uninfected, antibody-positive individuals and asymp-
tomatic infected individuals [13,14]. Unlike the situation in
Africa and Brazil, Leishmania-speciﬁc antibodies persist for
extended periods of time in the Indian subcontinent, empha-
sizing the importance of deﬁning biomarkers that reﬂect the
dynamics of asymptomatic infections [14]. PCR-based tests
directly demonstrating the presence of parasite nucleic acids
probably represent a more accurate tool for the assessment of
asymptomatic individuals, with the advantage of being sensitive
enough to detect very low levels of parasite DNA [15].
Serological and PCR-based techniques can complement each
other to establish how these biomarkers reﬂect asymptomatic
L. donovani infection. Given the potential availability of vaccines
against L. donovani, these tests could be used to identify
individuals or populations that will beneﬁt most from vacci-
nation.
To determine the utility of various tests, a group of
asymptomatic infected individuals in a region where L. donovani
is hyperendemic were examined over a period of 24 months
with serological tests, DAT and ELISA, as well as a sensitive
quantitative PCR test to deﬁne the dynamics of these
biomarkers.
Patients and Methods
Study design, ethics and parameters
We deﬁned an asymptomatic infected individual as a person
from a VL endemic area with no past history of VL or
post-kala-azar dermal leishmaniasis (PKDL), clinically healthy
and positive by the rK39 rapid test (Kalazar DetectTM; Inbios,
Seattle, WA, USA) in the ﬁeld using ﬁnger-prick blood. We
recruited 3849 clinically healthy people in the Harirampur
Union of subdistrict Trishal, Mymensingh district, where VL is
hyperendemic with a reported incidence of 65 per 10 000
people in 2007 (Trishal Hospital). Initial consent was obtained
from the head of the household to screen household members
based on past VL or PKDL history, then individual written
consent was obtained before enrolment in the study. Initial
screening was conducted using the Kalazar DetectTM rk39 rapid
diagnostic test (RDT) and 332 were found positive, with 200
deemed ﬁt to participate in the study based on no prior history
of VL or PKDL (50% were female and 35.5% were under
15 years). Fifty-six were then enrolled as study subjects based
on the availability of matching serum and DNA samples when
the study was initiated (baseline) and 12 months after initiation
(follow up) (Fig. 1a). All serological and PCR tests were
conducted on these 56 serum and DNA samples collected at
baseline and 12-month follow up (Fig. 1b). The enrolees were
monitored each month for clinical symptoms of VL during
household visits up to 24 months after study initiation, with
three of the 56 enrolees developing VL disease by 24 months.
They were referred to the study clinic where a qualiﬁed
medical ofﬁcer examined them following the diagnostic criteria
for VL of the National Guideline before referring them to the
Trishal Hospital for treatment (Fig. 1b) [16].
Sample collection and storage
Blood specimens were collected at enrolment and then at
12 months. Blood specimens were collected by venepuncture.
For DNA extraction, an aliquot of 2 mL was placed in an
EDTA-containing vacutainer and centrifuged at 2200 g for
20 min for separation of buffy coat. Collected buffy coat was
transported to the ICDDRB Parasitology Laboratory main-
taining the cold chain and DNA was isolated using a QIAamp
DNA blood mini kit (Qiagen, Hilden, Germany) as per the
manufacturer’s instructions. For serum preparation, 2 mL of
blood was placed in red-top vacutainers and allowed to clot at
room temperature for an hour and centrifuged for 5 min for
separation of serum. Collected serum was transported as
above.
Serological tests
DAT was performed according to the manufacturer’s instruc-
tions (KIT Biomedical Research, Amsterdam, the Netherlands)
with minor modiﬁcations [17]. Brieﬂy, in V-bottom 96-well
plates, healthy US control and test serum samples were serially
diluted two-fold starting at 1 : 400 in 0.9% sodium chloride
added 0.8% b-mercaptoethanol at a ﬁnal volume of 50 lL per
well. Antigen re-suspended in 50 lL of 0.9% sodium chloride
was then added per well. Each plate included at least two blank
wells containing only sample diluent. After brief mixing, plates
were covered and left undisturbed at room temperature for
18 h before reading. Samples were run in singlet per plate and
duplicated by a second researcher. Results were independently
scored by three readers. Each reader recorded the titre as the
last sample dilution at which agglutination was apparent. The
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titre for each sample was taken as the median score from the
three readers, and the scores from the two plates were
compiled to obtain a ﬁnal titre. In the event of disagreement
between duplicates, the higher of the two titres was chosen.
Samples with a ﬁnal titre of 1 : 1600 or higher were
considered positive.
Serum antibodies against L. donovani whole cell lysate
(WCL) and recombinant k39 were assessed by ELISA. In
brief, 0.5 lg/well of WCL or 0.1 lg/well of antigens at 50 lL/
well in 0.1 M PBS pH 7.2 were used to coat 384-microwell
plates (Corning, Tewksbury, MA, USA) at 4°C overnight. After
blocking with 1% bovine serum albumin in PBS/0.05%
Tween-20, serum samples at 1 : 100 dilutions were added to
wells in triplicate and allowed to incubate at room temper-
ature with shaking for 1.5 h. After washing, 1 : 5000 diluted
peroxidase-conjugated donkey anti-human IgG H + L chains
(Jackson ImmunoResearch, Westgrove, PA, USA) were added
for 1 h with shaking. Plates were developed with SureBlue
TMB Microwell peroxidase (Thermoﬁsher, Lafayette, CO,
USA) for 5 min and stopped with 0.1 M H2SO4. Plates were
read immediately at 450 and 570 nm (Synergy 2 plate reader,
Biotek, Winooski, VT, USA) and ﬁnal optical density (OD) was
recorded as the difference between the two. Mean values from
triplicate readings for each sample were calculated. A cut-off
value for positive results was determined as the mean OD of
non-endemic control sera from healthy US normal participants
plus two standard deviations. Sera from eight conﬁrmed VL
patients from Bangladesh and Sudan served as positive
controls.
DNA extraction and PCR tests
Genomic DNA was extracted from the buffy coat of blood
samples using the QiaAMP DNA blood mini kit (Qiagen) in the
ICDDRB Parasitology laboratory. An aliquot of DNA was
shipped to the Infectious Disease Research Institute, Seattle.
Quantitative detection of Leishmania DNA was performed on a
Individuals screened
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rk39 RDT (KaIa-azar DetectTM)
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FIG. 1. Study enrolment criteria, timeline and tests performed on study subjects (a) Out of 3839 individuals screened in the Mymensingh district of
Bangladesh, 332 tested positive by the rk39 rapid test; 200 of them were eligible for the study because they had no past history of visceral
leishmaniasis (VL)/post-kala-azar dermal leishmaniasis (PKDL). Of these, 56 were enrolled on the basis of availability of matching serum and DNA
samples at study initiation (baseline) and 12 months after initiation (follow up). (b) Timeline of sample collection and tests performed during the
course of the study. Serum and DNA were extracted from the 56 study subjects at baseline and 12-month follow up. After that they were monitored
for VL disease development according to the Bangladesh National Guidelines by monthly surveillance until 24 months.
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Roche LightCycler 480 system (Roche, Indianapolis, IN, USA)
using Taqman primers and probes; 5′- GCGACGTCCGT
GGAAAGAA-3′, 5′-GGCGGGTACACATTAGCAGAA-3′ and
reporter (FAM): 5′-CAACGCGTATTCCC-3′ (Applied Biosys-
tems Inc., Foster City, CA, USA). The custom gene assay was
developed using ABI FILEBUILDER 3.1 (open selection) from the
conserved region of Leishmania REPL repeats (L42486.1),
which can be detected in L. donovani and Leishmania infantum
[18,19]. For standard curves, L. donovani promastigotes were
spiked into uninfected human blood/paxgene mixtures to
provide a concentration of 1000 parasites/mL in duplicate,
allowed to incubate at room temperature for 4 h, and then
serially diluted with human blood/paxgene mixture to provide
a range of 1000–101 parasites/mL blood. The dilution set was
frozen at 20°C overnight, then DNA was extracted using the
QIAamp DNA Mini Kit. No template controls or blood from
healthy US donors was included in each assay. Samples were
initially examined in duplicate; for those samples that did not
amplify, or that had very late ampliﬁcation (≥40 cycles) the
assay was repeated in triplicate. Mean Cp values of ampliﬁca-
tion were extrapolated against the standard curve to enumer-
ate the number of parasites per mL of blood. Samples that
displayed no products at >40 cycles were considered negative.
A two-tailed, paired t-test was performed to determine
correlations between the circulating parasite DNA at baseline
and follow up.
Results
Quantitative PCR as a measure of circulating parasite DNA
The presence of L. donovani DNA was assessed by quantitative
PCR, which is sensitive enough to detect the DNA equivalent
of 0.01 L. donovani/mL of blood and can be accurately
extrapolated to a standard curve to measure the presence
of parasite DNA equivalents in the blood of study subjects.
The number of PCR-positives fell from 47 of the 56 study
subjects (84%) at baseline to 16 (28%) at 12-month follow up
(Table 1). One new PCR positive emerged at follow up while
40 positives at intake became PCR negative. The predicted
parasite burden in these samples was very low, the median
being 0.1 L. donovani DNA equivalents/mL of blood. A plot of
individual trends of PCR status through the study of the 40
study subjects who became negative at follow up illustrates a
highly signiﬁcant drop in PCR positivity at follow up, with a
p-value of 2.5*e9 by a paired, two-tailed Student’s t-test
(Fig. 2a). The 16 who remained positive at follow up showed
similar parasite DNA contents at baseline and follow up with
one negative gaining detectable parasite DNA at follow up
(Fig. 2b). The data suggest that the presence of L. donovani
DNA is transient, consistent with results obtained in a larger
survey of asymptomatic children in Brazil [20].
DAT provides an incomplete indication of asymptomatic
infection
DAT is a standard test, developed primarily for serological
conﬁrmation of VL. When applied to sero-evaluation of
asymptomatic individuals, DAT positivity was 57%, both at
baseline and at 12-month follow up (Table 1). Thirty-two
study subjects were DAT positive at baseline with 30 of the 32
remaining positive at follow up (Table 1). At follow up, two
new positives emerged. At baseline and follow up, the median
dilution at which agglutination was observed remained 3200
(Fig. 3a). Correlation of DAT with PCR at baseline was about
TABLE 1. Summary of study outcome. Number and per-
centages of study subjects who tested positive by the
indicated tests at baseline and 12-month follow up including
those that became negative and new positives detected at
follow up
Diagnostic test
Positive at
baseline (%)
Positive at
12-month
follow up
(%)
Became
negative at
follow up
Became
positive
at follow
up
Direct agglutination
test
32 (57) 32 (57) 2 2
Leishmania donovani
whole cell lysate
ELISA
46 (82) 42 (75) 8 4
rk39 ELISA 50 (89) 51 (92) 1 2
Quantitative PCR 47 (84) 16 (28) 32 1
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FIG. 2. Leishmania donovani DNA equivalents measured by quantita-
tive PCR, quantiﬁed by extrapolating to a standard curve with known
numbers of parasite. (a) Progression of L. donovani DNA loads of the
40 study subjects who tested PCR negative at 12-month follow up. (b)
Progression of L. donovani DNA loads of the 16 study subjects who
tested PCR positive at 12-month follow up. Each line represents an
individual tested at baseline and follow up and n represents the number
of individuals. **L. donovani DNA equivalents at baseline and follow up
were signiﬁcantly different as measured by a p value of 2.5*e9 by a
paired, two-tailed t-test.
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64% whereas two PCR negative samples were DAT positive
(Fig. 4a). We then compared DAT and PCR proﬁles at follow
up to see how the dynamics of Leishmania-speciﬁc antibodies
correlates to parasite DNA. DAT proﬁles at follow up
revealed poor correlation to PCR. Twenty-two of the 40
PCR negatives at follow up (55%) remained DAT positive, two
among them being new seroconverts (Fig. 4a). DAT proﬁles of
the 16 PCR positives at follow up reveal a 63% correlation,
with ten also remaining DAT positive (Fig. 4b).
ELISAs indicate persistent presence of antibodies
To provide comparability between DAT and ELISA, we used
L. donovani WCL as the coating antigen to detect anti-leish-
mania antibodies. At baseline, 46 individuals were positive for
antibodies against WCL (82%) of which 38 remained positive
at the 12-month follow up, with four new seroconverts (75%)
(Table 1). Similar to the results obtained with DAT, the
median OD was relatively unchanged over time, being 2.5 at
baseline and 2.0 at follow up (Fig. 3b). At baseline, L. donovani
WCL positivity correlated well with PCR positivity, with 40 of
the 47 PCR positives also testing positive for L. donovani WCL
antibodies (85% correlation) but seven of the nine PCR
negatives also testing positive for L. donovani WCL antibodies
(78%) (Fig. 4a). At follow up, correlation between PCR and the
L. donovani WCL ELISA was higher than with DAT, with 75%
testing positive or 12 out of 16 PCR positives (Fig. 4b). But
80% of PCR negatives at follow up (32 out of 40 individuals)
also remained positive by L. donovani WCL ELISA (Fig. 4b).
Recombinant rk39 is a well-deﬁned diagnostic antigen that
has been used in both ELISA and RDT [21,22]. However, tests
composed of the rk39 antigen have also been used, in an
off-label manner, for epidemiological screening, as opposed to
only for diagnosis. Consistent with initial inclusion of asymp-
tomatic individuals based on rk39 RDT positivity, antibodies
against rk39 were detected in sera of most study subjects at
both baseline and follow up by ELISA. At baseline, 50 (89%)
tested positive by rk39 ELISA, of whom 49 remained positive
at follow up with two new seroconverts (92%) (Table 1). The
median OD remained relatively unchanged at 2.8 and 2.9,
respectively, between these times (Fig. 3c). Though rk39
positivity correlated well with PCR positivity at baseline, with
89% or 42 of the 47 PCR positives also being rk39 positive,
similar to the L. donovani WCL ELISA, eight of the nine PCR
negatives at baseline (89%) remained rk39 positive (Fig. 4, top).
Among the 16 PCR positives at follow up, 75% or 12 remained
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FIG. 3. Distribution of seroreactivity of asymptomatic individuals at
baseline and follow up. (a) Comparison of the reciprocal serum
dilution at which agglutination was observed by direct agglutination
test of individuals at baseline (closed triangles) and follow up (open
triangles). Black line represents cut-off for positivity at 1600. (b)
Comparison of optical density (OD) at 450 nm of individuals at
baseline and follow up by antibody detection ELISA against Leishmania
donovani whole cell lysate (WCL; closed and open diamonds) along
with non-endemic controls (dotted diamonds). Black line represents
cut-off OD for positivity at 1.05. (c) Comparison of OD at 450 nm of
individuals at baseline and follow up by antibody detection ELISA
against rk39 (closed circles) along with non-endemic controls (dotted
circles). Black line represents cut-off OD for positivity at 0.89. Medians
for each distribution are represented by black bars. No signiﬁcant
differences between baseline and follow-up measurements were seen
for any of the serological tests.
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rk39 ELISA positive. But 95% of PCR negatives at follow up (38
out of 40) still remained rk39 ELISA positive attesting to a
poor correlation between rk39 ELISA and PCR, very similar to
the other serological tests used in this study (Fig. 4, bottom).
Hence, a persistent antibody response to L. donovani WCL and
rk39 was seen at baseline and at 12-month follow up. The
serological results of all study subjects at baseline and follow
up relative to PCR are represented in Fig. 6.
Serological tests are complementary
We then compared the complementation among the three
serological tests. The L. donovani WCL ELISA detected ﬁve out
of six rk39 ELISA-negative individuals (83% complementarity)
at baseline whereas DAT could detect three of six (50%
complementarity) (Fig. 5a, left). With two individuals being
positive by both tests, one was detected only by DAT and
three were detected only by L. donovani WCL ELISA (Fig. 6).
At follow up, L. donovani WCL ELISA detected three out of
ﬁve rk39-negative individuals (60% complementarity) com-
pared with two by DAT (40% complementarity) (Fig. 5a, right).
Because DAT positivity was lower than ELISA positivity in this
study and DAT is a widely used diagnostic test in the Indian
sub-continent we asked whether ELISA could complement
DAT. At baseline, 21 of the 24 DAT negatives were positive by
rk39 ELISA with the trend remaining the same at follow up
(Fig. 5b). Of the 24 DAT negatives at baseline, 20 were
positive by L. donovani WCL ELISA and 18 of the 24 DAT
negatives at follow up were positive by L. donovani WCL ELISA
(Fig. 5b). Both DAT seroconverts at follow up were positive
by rk39 ELISA whereas one was positive by L. donovani WCL
(Fig. 6).
Discussion
Disease intervention programmes, particularly disease elimi-
nation programmes, will beneﬁt from proactive identiﬁcation
of high-risk individuals. A comprehensive application of
biomarker-based tests for diseases in which humans are the
primary or only source of infection can make such identiﬁca-
tion possible. An excellent example of a disease to which this
strategy may be applied is VL. Because VL in the Indian
subcontinent is anthroponotic, identifying asymptomatic
infected individuals should be considered a priority within
kala-azar elimination programmes [23]. Developing tools that
can predict progression to VL disease will lead to early
intervention and treatment, two goals of the elimination
programme [6]. In previous studies to identify such tools in
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FIG. 4. Correlation between quantitative PCR (qPCR) and serological tests in asymptomatic individuals. The distribution of qPCR positive and
negative individuals as detected by direct agglutination test (DAT), Leishmania donovani whole cell lysate (WCL) and rk39 ELISA has been depicted. (a)
Correlation of qPCR positivity and negativity with DAT, L. donovani WCL and rk39 ELISA at baseline. Number of individuals positive or negative
followed by percent positive or negative in parenthesis. (b) Correlation of qPCR positivity and negativity with DAT L. donovani WCL and rk39 ELISA
at 12-month follow up.
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India, the rk39 RDT and DAT have proven to be of limited
utility in predicting progression to disease, because the tests
did not correlate with each other nor did seroconversion
correlate with disease progression [11,23,24]. To develop
better tools to reﬂect the dynamics of asymptomatic infection,
we wanted to determine the utility of a direct method
(quantitative PCR) and indirect methods (serology) for
detecting asymptomatic L. donovani infection. We conducted
a study on 56 rk39 RDT-positive individuals in an area of VL
endemicity in Bangladesh using DAT and ELISA to detect
antibodies and quantitative PCR to detect DNA over
24 months. Fifty-four of the 56 enrolees at baseline and 55
of the 56 enrolees at follow up tested positive by any of the
serological tests used (Fig. 6). This indicates that in endemic
areas, antibodies to Leishmania antigens can be encountered in
the absence of disease, mirroring the observation that
circulating antibodies are observed over extended periods
after cure [13,14]. At baseline, the PCR results agreed closely
with serological tests, but at the 12-month follow up the
number of PCR positives was signiﬁcantly decreased while
serology positives remained relatively unchanged (Table 1 and
Fig. 6). However, given the low parasite burden of asymp-
tomatic infections, it is unclear whether the results reﬂect the
actual number of individuals with active disease. Studies are
underway to determine the robustness of PCR methods to
detect low parasite burdens.
Though all 56 study subjects tested positive by the rk39
RDT at study intake, six baseline samples tested negative by
ELISA against rk39 (Fig. 5, top). This discrepancy can be
attributed to both differences in the sensitivity of the rapid test
between whole blood and serum and the use of a quantitative
ELISA with stringent cut-offs to identify positives, highlighting
the utility of standardized tests with deﬁned cut-offs for
sensitivity when screening populations. Rapid tests may be
more suitable to conﬁrm infection in the presence of
symptoms. The complementation of the few rk39-negative
sera by the other serological tests underlines the utility of a
broader panel of antigens provided by both lysed or
freeze-dried promastigotes to detect early infection (Figs 5
and 6). Our data indicated that L. donovani WCL ELISA
complemented rk39 better than DAT. A quantitative test such
as ELISA may be more sensitive in detection compared with
DAT, in which agglutination is visually assessed.
DAT is used extensively in the Indian subcontinent for both
screening and detection [11,25,26]. Similar to other reports,
our DAT results did not correlate with PCR [15,27]. A study
conducted in the VL-endemic Terai region of Nepal found PCR
positivity among healthy individuals with no history of past VL
to be 17.6% and among treated VL patients to be 25.6%, while
DAT positivity in these groups was 5.5% and 95%, respectively
[27]. In the same study, DAT positivity was higher and
correlated well with PCR in healthy household contacts of
persons with present or past VL disease, conﬁrming previous
observations that constant exposure to VL patients increases
the risk of acquiring infection [10,23–25].
Among the 56 study subjects, only three went on to
develop VL within the 24-month study period, about 5%. Of
those, two individuals remained consistently positive by PCR
Baseline
rk39 ELISA Negative
6  
12 month follow-up
3 (50%) 3 (50%)
5 (83%) 1 (17%)
Positive Negative Positive Negative
Positive Negative Positive Negative
DAT Negative 
24
21 (88%) 3 (12%)
20 (83%) 4 (17%)
rk39 ELISA
Ld WCL ELISA
DAT
Ld WCL ELISA
2 (40%) 3 (60%)
3 (60%) 2 (40%)
DAT
Ld WCL ELISA
rk39 ELISA Negative
5  
DAT Negative 
24
21 (88%) 3 (12%)
18 (75%) 6 (25%)
rk39 ELISA
Ld WCL ELISA
12 month follow-upBaseline
(a)
(b)
FIG. 5. Complementation of serological tests in asymptomatic individuals. Detection ofrk39 and direct agglutination test (DAT) -negative
individuals. (a) Complementation of rk39 ELISA negativity by DAT and Leishmania donovani whole cell lysate (WCL) ELISA at baseline and 12-month
follow up. (b) Complementation of DAT negativity by rk39 and L. donovani WCL ELISA at baseline and 12-month follow up.
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and serology, while the other was PCR positive at baseline and
follow up but was consistently negative by all serological tests
at baseline and positive by only rk39 ELISA at follow up. DNA
has a shorter half-life than antibodies, and its presence in blood
constitutes direct evidence of ongoing infection [14,28].
Appearance of DNA could also precede the appearance of
detectable antibodies, signalling recent infections. In a canine
model of VL, circulating parasite DNA was detected by PCR
4 months after infection, while Leishmania-speciﬁc antibodies
were detected by ELISA 6 months after infection, reﬂecting
the different kinetics of these biomarkers [29]. Because PCR
positivity was a shared feature of those individuals that
progressed to disease, sensitive and standardized DNA
ampliﬁcation platforms will be useful tools in active surveillance
for asymptomatic infections and effectively complement stan-
dardized point-of-care serological tests. The small number of
individuals who are both serology and PCR positive may
represent clusters or hyperendemic foci within regions where
Leishmania is endemic that are at the highest risk of transmit-
ting the parasite or progressing to disease. Hence, tests that
detect the presence of parasite DNA and Leishmania-speciﬁc
antibodies will identify those individuals likely to beneﬁt most
from a vaccine or other intervention [30]. Because vaccines
against VL are in development, the tests used together could
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FIG. 6. Serological and PCR test status of all samples at baseline and 12-month follow up, compared side-by-side. Light grey shaded boxes indicate
positive status and dark grey boxes indicate negative status
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help to set enrolment criteria for trials as well as deﬁning
end-points to assess vaccine efﬁcacy.
A limitation of this study was the small sample size, which
may be the reason for lower disease conversion rates (5%)
than previously reported [11,23]. We are also aware that,
because positivity in the rk39 RDT was the criterion for initial
screening in this study, we may have preselected individuals
who were already high in antibody titres against Leishmania.
This study was undertaken to identify tools that can reveal
how asymptomatic infection emerges and contributes to VL
incidence and how to design vaccine trials [29]. To clearly
understand the utility of the tools we generated, they should
be used in longitudinal studies on large populations within
endemic regions with no preselection except for past VL
disease. Such a study will help us better use these biomarkers
in the detection of asymptomatic infection and design effective
programmes for disease control.
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